Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large B-cell lymphoma (DLBCL) with unique clinical, histological and biological features. 1 Molecular cytogenetics and gene expression profiling studies revealed that PMBL shares a number of features with classical Hodgkin's lymphoma (cHL). Similar to cHL, PMBL exhibits the presence of phophorylated (P) signal transducer and activator of transcription (STAT) 6 proteins. 2, 3 Interestingly, the activation of STAT6 has been linked to autocrine secretion of interleukin (IL) 13 in cHL which, however, is absent in PMBL. Janus kinase (JAK) 2 activation and/ or overexpression has been suggested to participate in STAT6 activation in PMBL, whereas the other factors involved remain elusive. 2 The binding of IL-4 or IL-13 cytokines to their receptors induces receptor-associated JAK activation, leading to receptor phosphorylation and STAT6 activation. The supressor of cytokine signaling (SOCS) proteins suppress cytokine signaling by binding to and inhibiting the activity of JAKs, by competing with STATs for phosphorylated-binding sites on receptors, or by targeting bound signaling proteins for proteasomal degradation. 4 There is increasing evidence that the loss of SOCS-1 function is critical in the development and progression of several cancers. In many hematopoetic malignancies, as well as in solid tumors, SOCS-1 was found to be silenced by aberrant DNA methylation. SOCS-1 mutations or deletions have been recently detected in 45% of PMBL cases. 5 The two PMBL-derived cell lines Karpas1106 and MedB-1 bear abnormalities in the SOCS-1 gene. Karpas1106 has biallelic SOCS-1 deletions, 6 whereas MedB-1 has biallelic SOCS-1 loss of function mutations inherited from the parental tumor, which are responsible for sustained activation of JAK2 and STAT5 phosphorylation. 5 Adding to the relatedness of PMBL and cHL, SOCS-1 is also mutated in more than 40% of cHL samples and in 60% of cHL cell lines. 6 As SOCS-1 downregulates the kinase activity of JAKs and is a negative feedback regulator of STATs activity, we investigated whether SOCS-1 defects participate in the activation of STAT6 in PMBL and searched for cellular and molecular targets of this deregulated pathway.
STAT6 DNA-binding activity was detected in the nuclear extracts of both the MedB1 and Karpas1106 PMBL cell lines (Figure 1a ). These cell lines were co-transfected with a luciferase reporter plasmid (Panomic, Redwood City, CA, USA) containing, or not, three copies of the STAT6 DNA-binding site of the human SOCS-1 promoter (TTCCGAGGAA) together with a mock or wild-type (wt) SOCS-1 expression vector, using the Nucleofector device (Amaxa, Cologne, Germany). In both cell lines, transcription from a minimal promoter was strongly enhanced upon addition of three STAT6 DNA-binding sites (Figure 1b) . Transfection of these cell lines with a wt SOCS-1 expression vector induced a 59% reduction in P-STAT6 relative to total STAT6 protein in Karpas1106, and a 46% reduction in MedB-1 (Figure 1c ). Wt SOCS-1 expression abrogated transcription from the 3 Â STAT6-luciferase reporter construct down to the basal level of the minimal promoter in Karpas1106 cells, whereas in MedB-1 cells this reduction was about 60% (Figure 1b) . The partial effect observed in MedB-1 cells may be due to the fact that this cell line carries mutated SOCS-1 genes, encoding C-terminal truncated proteins (Figure 1d ), whereas Karpas1106 does not express any endogenous SOCS1 proteins. Normal SOCS proteins contain a central SH2 domain, responsible for their binding to the P-tyrosines of cytokine receptors and JAKs, and a 40 amino-acid C-terminal domain, the SOCS box. This domain recruits an E3 ubiquitin ligase complex targeting bound proteins for proteasomal degradation. MedB-1 mutant SOCS-1 proteins carry a seven amino-acid deletion or a frameshift in the SOCS box region. 5 These mutant SOCS-1 proteins may still bind to phosphorylated receptors and kinases, by their SH2 domain, but lack the ability to mark proteins for degradation and could compete with exogenous wt SOCS-1 protein. The strong basal STAT6 activity and the partial effect of wt SOCS1 expression on STAT6 activity in MedB-1 cells suggests that proteasomal degradation plays a critical role in the mechanism, whereby SOCS-1 normally inhibits JAK/STAT signaling in these cells.
We next analyzed the cellular effects induced by wt SOCS-1 expression in PMBL cell lines. Quantification of total cell death by Nicoletti (propidium iodide) staining demonstrated an increase in the number of cells with subG1 DNA content in wt SOCS-1-transfected cells compared with mock-transfected cells up to 4.5 fold in Karpas1106 (24 ± 2.5 versus 5.3 ± 1.3%) and 3.2 fold in MedB-1 (29 ± 3 versus 9 ± 0.8%). May Grü nwald Giemsa staining revealed condensed and fragmented nuclei characteristic of apoptosis in about 20% of the MedB-1 cells transfected with the wt SOCS-1 expression vector (Figure 1e) . To quantify the effect of SOCS-1 expression on the induction of apoptosis in these cells, green fluorescent protein (GFP) -positive transfected cells were analyzed by immunohistochemistry for the presence of activated caspase 3. As shown in Figure 1f , SOCS-1 expression induced a 3.3 fold increase in the apoptotic cell fraction. By contrast, no morphologic feature characteristic of apoptosis was observed in wt SOCS-1-transfected Karpas1106 cells, which, instead, exhibited membrane leakage and nuclear fading that we interpreted as signs of necrosis ( Figure 1e , right panel). This alternative mode of death turned out to be due to a fundamental apoptosis defect of this cell line, which proved to have absent or reduced expression of p53, Apaf-1 and caspase 3 proteins and to be resistant to classical apoptotic stimuli, such as CD95 (Fas) stimulation or staurosporin treatment (data not shown). This phenoptype may be due to the deletion of p53-inducible genes previously reported in this cell line. 7 Altogether, these results indicate that SOCS-1 gene defects have pro-survival effects in both PMBL cell lines.
Signal Letters to the Editor (GGAAGCAGGAAGAACTCAAGTT), led to a similar decrease in total STAT6 ( Figure 3D ) and induced a 2.5 fold increased cell death as assessed by Nicoletti staining (subG1 cells ¼ 11 ± 1.2% in STAT6 shRNA versus 4.4±0.7% in control shRNA). As this effect could be due to the activation of an interferon response by siRNA, we tested whether transfection increased STAT1 levels or its phosphorylation. No significant differences between control and STAT6 siRNA-treated cells were observed under these conditions (Figure 2 ). In four independent propidium iodide (PI) staining experiments, we observed that STAT6 siRNA transfection of MedB-1 cells induced a decrease in the S phase cell fraction (43 ± 12% in control siRNAtransfected cells, 29±10% in STAT6 siRNA-transfected cells, Po0.01). This decrease was confirmed by quantitative cell cycle analysis of the cell populations that had been stained for incorporated BrdU (Table 1) . Overall, a 67% decrease in total STAT6 protein expression led to a 33% decrease of the S phase cell fraction, both in PI and BrdU staining experiments. STAT6 siRNA did not affect Karpas1106 and SUDHL4 proliferation. Altogether, these data show that STAT6 activation positively regulates proliferation and cell survival in MedB-1 cells.
Exogenous wt SOCS-1 expression, although leading to a decrease in P-STAT6 (Figure 3d ) did not affect MedB-1 cell cycle progression (data not shown) and clearly increased the apoptotic rate, as the cells exhibited morphologic features of apoptosis, activated caspase 3 staining and the presence of hypodiploid DNA. Hence, it is likely that exogenous wt SOCS-1 expression affects targets other than STAT6, which interfere with proliferation and apoptotic signaling, and are responsible for the different phenotypes observed in exogenous wt SOCS-1-expressing and STAT6 siRNA-suppressed cells. Such targets may be STAT5 5 and/or STAT1, known to be expressed in PMBL cells. As we did not observe significant STAT5 or STAT1 DNA-binding activity in MedB-1 cells, these factors might act through non-transcriptional cytoplasmic effects.
Surprisingly, STAT6 silencing did not affect cell survival or proliferation in Kapas1106. It should be noted that the level of STAT6 activation is lower in Karpas1106 than in MedB-1 (Figure 1a ). This may be due to differences in JAK2 deregulation, as constitutive phosphorylation of JAK2 was detected in MedB-1, but not in Karpas1106 cells. 2 Furthermore, the proliferation rate of Karpas1106 is higher than that of MedB-1 and the cytogenetic abnormalities of these cell lines differ. Hence, it is highly probable that this particular cell line has accumulated a number of additional defects that renders it STAT6 independent, as opposed to MedB-1.
Signal transducer and activator of transcription 6 regulates the transcription of numerous target genes through its binding to GAS sequences and its interaction with the co-activators, p100 and/or CBP/P300, and other transcription factors, such as C/ EBPb, PU.1 and nuclear factor-kB. The BCL-XL gene, which regulates the apoptotic and autophagic cell death pathway, contains a STAT6-binding motif. To test whether BCL-XL is responsible for the above effects mediated by the SOCS-1/ STAT6 pathway, we analyzed the in vivo binding of STAT6 to the promoter of this gene using the chromatin immunoprecipitation (ChIP) Assay kit (Biomol, Hamburg, Germany). The BCL-XL promoter region was amplified in MedB-1 and Karpas1106 chromatin precipitated with an anti-STAT6 antibody, but not with a control (anti-PTPN1) antibody, whereas a control promoter region from histone H2B gene was not amplified, indicating specific binding of STAT6 to the BCL-XL gene regulatory region in PMBL-derived cell lines (Figure 3a) . To confirm the regulation of this target, we analyzed mRNA levels in MedB-1, Karpas1106 and SUDHL4 cells transfected with control or STAT6 siRNA in three independent experiments, using real time quantitative reverse transcription-PCR, with BCL-XL/BCL2L1 (Hs00236329_m1) and TBP (Hs00427620_m1) Table 1 Viability and cell cycle analysis of MedB-1 cells transfected with siRNA
Abbreviations: STAT6, signal transducer and activator of transcription 6; siRNA, small interfering RNA. The mean ± s.d. of three independent experiments is shown. Paired Student's t-test was used to compare cell fractions.
inventoried TaqMan gene expression assays, on an ABI7000 System (Applied Biosystems, Courtaboeuf, France). STAT6 siRNA induced a significant decrease in the level of total STAT6 protein in all cell lines and was associated with a significant decrease of BCL-XL mRNA levels in MedB-1 cells, but not in Karpas1106 or SUDHL4 cells (Figure 3b ). The 45% decrease in the amount of BCL-XL mRNA was associated with a 37.5% decrease in BCL-XL protein levels in MedB-1 (Figure 3c) . A to the manufacturer's instructions, with minor modifications as previously described. 8 Primers specific for histone H2B promoter were used as negative control. Additional negative controls included chromatin precipitated with anti-PTP1B antibody and a sample to which no antibody was added (no AB). DNA purified from the precleared chromatin solution was used as total input control (input). unresponsiveness could explain the absence of cell death effects after STAT6 siRNA transfection and could be due to the activation of other transcription factors, such as nuclear factorkB, known to control BCL-XL expression.
To test whether the phosphorylation status of STAT6 and its nuclear translocation coincides with the expression of BCL-XL protein in vivo, we studied their expression in a series of 28 tumor samples, collected between 1988 and 1998 in the Institute of Pathology of Ulm. Twenty-six out of 28 PMBL cases exhibited nuclear staining for P-STAT6 in more than 40% of the neoplastic cells and 25 out of 28 PMBL cases exhibited cytoplasmic staining for BCL-XL in more than 50% of the neoplastic cells. There was a clear correlation between nuclear P-STAT6 accumulation and BCL-XL expression as 25 out of 28 cases (89%) showed staining for both (Figure 3e , A and C), whereas 2 out of 28 cases (7%) were negative for both (Figure 3e, B and D) . Actually, there was just one single case with a high percentage of P-STAT6 positive lymphoma nuclei and a very low percentage of BCL-XL-positivity within the lymphoma cell compartment. This might be due to the absence of transcriptional activators required to activate BCL-XL transcription in association with STAT6, such as nuclear factor-kB or Ets transcription factors. According to the linear correlation analysis, we found a Pearson correlation coefficient of r ¼ 0.39 (Po0.05) between the percentage of the cells immunoreactive for BCL-XL and the percentage of the cells immunoreactive for P-STAT6. In summary, these data strongly suggest that STAT6 upregulates BCL-XL expression not only in MedB-1 cells but also in PMBL tumors.
Altogether, our results provide evidence that SOCS-1 gene defects strongly contribute to constitutive STAT6 activation and promote cell survival in PMBL cell lines. STAT6 regulates cell proliferation and survival and BCL-XL expression in MedB-1 cells. Its association with BCL-XL expression in primary PMBL cases suggests that the deregulation of the SOCS1/STAT6 pathway plays a critical role in PMBL pathogenesis.
